BioNano Genomics Inc vs Blackstone Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Blackstone Inc trades at $129.56 (market cap $152.15B). The key difference: Blackstone Inc is far larger — about 11526.5× BioNano Genomics Inc's market cap, and Blackstone Inc pays a 3.99% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | BX | |
|---|---|---|
Market Cap | $13.20M | $152.15B |
Sector | Health | Financials |
52-Week High | $4.92 | $188.68 |
52-Week Low | $1.09 | $102.12 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 3.99% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →